Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti–Programmed Death-Ligand 1 and Anti–Vascular Endothelial Growth Factor
VEGFR2-targeted therapy not only suppressed tumor angiogenesis but also inhibited CSCs and enhanced antitumor immune activity, suggesting its potential utility as a second-line treatment following Atezolizumab/Bevacizumab.
Authors
- Gen Sugiyama
- Yasunori Iwata (ORCID: https://orcid.org/0000-0002-4756-5207)
- Hideo Takayama (ORCID: https://orcid.org/0000-0001-8247-483X)
- Hikari Okada (ORCID: https://orcid.org/0009-0009-7218-9619)
- Masao Honda (ORCID: https://orcid.org/0000-0003-3050-5854)
- Tomoyoshi Chiba
- Tomoyuki Hayashi (ORCID: https://orcid.org/0000-0002-4416-2912)
- Akihiko Kida (ORCID: https://orcid.org/0000-0002-4380-5437)
- Saiho Sugimoto
- Keisuke Sako (ORCID: https://orcid.org/0000-0002-8272-5085)
- Hajime Takatori (ORCID: https://orcid.org/0000-0002-6680-2925)
- Kouki Nio (ORCID: https://orcid.org/0000-0002-0971-8313)
- Y. Kawakami (ORCID: https://orcid.org/0000-0001-5711-2095)
- Masaki Nishitani (ORCID: https://orcid.org/0000-0003-3328-2553)
- Taro Yamashita (ORCID: https://orcid.org/0000-0002-3383-9131)
- Kazuki Nagai
- Tetsuro Shimakami (ORCID: https://orcid.org/0000-0002-8308-4056)
Institutions
- Kanazawa University (JP)
Publication Details
- Journal
- Gastro Hep Advances
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.gastha.2025.100778
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science